Paper24687169
Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial.
Lexis CP and 23 others. JAMA, 2014. Cited by 148 papers, by iCite.
Cite this record
ConductScience Library. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. Papers, record 24687169. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24687169
- Disease
- heart failure311 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hypoglycemic Agents | Major topic |
| Metformin | Major topic |
| Myocardial Infarction | Major topic |
| Ventricular Dysfunction, Left | Major topic |
| Ventricular Function, Left | Major topic |
| Aged | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Magnetic Resonance Imaging | |
| Male | |
| Middle Aged | |
| Percutaneous Coronary Intervention | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01217307 | Metformin to Reduce Heart Failure After Myocardial Infarction | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 24736756 | Acute coronary syndromes: Metformin not associated with improved left ventricular function after STEMI in patients without diabetes mellitus. | https://conductscience.org/library/papers/24736756 | PubMed |
| Comment in | 25617933 | Study answers long-standing question about metformin after heart attack. | https://conductscience.org/library/papers/25617933 | PubMed |
Cited by80
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 148 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42920579 | Sex-dependent transcriptional and imaging responses to metformin in young-adult mice with SuHx-induced pulmonary arterial hypertension. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42920579 | PubMed |
| 42351790 | AMPK Signalling in Heart Failure: From Metabolic Sensor to Context-Dependent Therapeutic Target. | Biomedicines | 2026 | https://conductscience.org/library/papers/42351790 | PubMed |
| 42156933 | Sex differences in cardiac structure and function following ST-segment elevation myocardial infarction. | Sci Rep | 2026 | https://conductscience.org/library/papers/42156933 | PubMed |
| 42047732 | Metformin as a potential therapeutic agent in broken heart syndrome: Targeting AMPK-dependent cardio-protection and microvascular function. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42047732 | PubMed |
| 41704279 | Repurposing metformin for cardioprotection: mechanisms and therapeutic potential across cardiovascular pathologies. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41704279 | PubMed |
| 41090739 | Myocardial Ischemia/Reperfusion Injury: Molecular Insights, Forensic Perspectives, and Therapeutic Horizons. | Cells | 2025 | https://conductscience.org/library/papers/41090739 | PubMed |
| 40978514 | The immune checkpoint TIM-3/HMGB-1 axis in myocardial infarction. | NPJ Cardiovasc Health | 2025 | https://conductscience.org/library/papers/40978514 | PubMed |
| 40582648 | Emerging uncertainty on the anti-aging potential of metformin. | Ageing Res Rev | 2025 | https://conductscience.org/library/papers/40582648 | PubMed |
| 40423634 | Type 2 Diabetes Mellitus: A Metabolic Model of Accelerated Aging - Multi-Organ Mechanisms and Intervention Approaches. | Aging Dis | 2025 | https://conductscience.org/library/papers/40423634 | PubMed |
| 39685849 | Exogenous Ketones in Cardiovascular Disease and Diabetes: From Bench to Bedside. | J Clin Med | 2024 | https://conductscience.org/library/papers/39685849 | PubMed |
| 39235508 | Multi-omics analysis of the lipid-regulating effects of metformin in a glucose concentration-dependent manner in macrophage-derived foam cells. | Cell Biochem Biophys | 2024 | https://conductscience.org/library/papers/39235508 | PubMed |
| 39155333 | Association of fibrotic markers with diastolic function after STEMI. | Sci Rep | 2024 | https://conductscience.org/library/papers/39155333 | PubMed |
| 38094689 | Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial. | JACC Basic Transl Sci | 2023 | https://conductscience.org/library/papers/38094689 | PubMed |
| 38057783 | Impact of stress hyperglycemia ratio, derived from glycated albumin or hemoglobin A1c, on mortality among ST-segment elevation myocardial infarction patients. | Cardiovasc Diabetol | 2023 | https://conductscience.org/library/papers/38057783 | PubMed |
| 36806755 | Higher mitochondrial DNA copy number is associated with metformin-induced weight loss. | Commun Med (Lond) | 2023 | https://conductscience.org/library/papers/36806755 | PubMed |
| 36747244 | Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial. | Cardiovasc Diabetol | 2023 | https://conductscience.org/library/papers/36747244 | PubMed |
| 36690932 | Predictors of adverse diastolic remodeling in non-diabetic patients presenting with ST-elevation myocardial infarction. | BMC Cardiovasc Disord | 2023 | https://conductscience.org/library/papers/36690932 | PubMed |
| 36211585 | Effect of metformin on adverse outcomes in T2DM patients: Systemic review and meta-analysis of observational studies. | Front Cardiovasc Med | 2022 | https://conductscience.org/library/papers/36211585 | PubMed |
| 36052760 | Protective effects of metformin in various cardiovascular diseases: Clinical evidence and AMPK-dependent mechanisms. | J Cell Mol Med | 2022 | https://conductscience.org/library/papers/36052760 | PubMed |
| 35638331 | Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. | J Diabetes Investig | 2022 | https://conductscience.org/library/papers/35638331 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| METFORMIN | CHEMBL1431 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1431 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24687169
GET https://conductscience.org/api/papers/v1/24687169/authors?page=2